Better Buy: AbbVie vs. Gilead Sciences
AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD) are names you might be hearing a lot these days. AbbVie is in the process of acquiring Botox maker Allergan (NYSE: AGN) to boost its growth potential and reduce its reliance on the world's current top-selling drug, Humira. Meanwhile, Gilead's investigational coronavirus treatment, remdesivir, is in clinical studies, putting that company in the spotlight.
So far this year, optimism about finding a coronavirus treatment has been the wind in Gilead's sails, lifting the stock 24%. Over the same time, AbbVie shares fell by 7%. I like these stocks and would be happy to add both of them to my portfolio. But if I had to choose just one ... well, let's have a closer look and see which offers the best buying opportunity right now.
Image source: Getty Images.
Source Fool.com
